RESUMEN
A field experiment was carried out during Rabi season 2019-20 at wheat and barley section research area of CCS Haryana Agricultural University, Hisar. The experiment was comprised of three nitrogen doses (N1-60, N2-75 and N3- 90 kg N/ha) as main plot treatments and four seed rates (S1- 87.5, S2- 100, S3- 112.5 and S4-125.0 kg/ha) as sub plot treatments. With four replications, experiment was laid out in split plot design. Based on the research investigation, it was found that nitrogen dose and seed rate both had significantly influenced the yield attributes and yield of dual purpose barley Among nitrogen doses, 90 kg/ha being at par with 75 kg/ha recorded significantly higher grain yield (4895 kg/ha), biological yield (12220 kg/ha) and green fodder yield (3706 kg/ha) which were 9.7, 12.0 and 15.1 percent higher than nitrogen dose of 60 kg/ha, respectively due to higher yield attributes i.e. number of effective tillers (85.08), number of grains per spike (44.15), number of spikelets per spike (23.10), spike length (7.47) and test weight (37.82) with nitrogen dose 90 kg/ha which were 8.5, 5.1, 7.9, 11.4 and 4.8 percent higher than nitrogen dose of 60 kg/ha, respectively. Among seed rates, 125.0 kg/ha closely followed by 112.5 kg/ha recorded significantly higher effective tillers (85.11), grain yield (4922 kg/ha), biological yield (12181 kg/ha), green fodder yield (3729 kg/ha) which were 8.0, 11.0, 11.8 and 16.7 per cent higher than seed rate of 87.5 kg/ha, respectively.
RESUMEN
As of August 16,2021,there have been 207,173,086 confirmed cases and 4,361,996 deaths due to the coronavirus disease(COVID-19),and the pandemic remains a global challenge.To date,no effective and approved drugs are available for the treatment of COVID-19.Angiotensin-converting enzyme 2(ACE2)plays a crucial role in the invasion into host cells by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the etiological agent of COVID-19.Notably,ACE2 density is influenced by medical con-ditions,such as hypertension,or by drugs,including angiotensin-converting enzyme inhibitors(ACEIs)and angiotensin receptor blockers(ARBs),which can change the fate of SARS-CoV-2 infectivity.ACE2 is a target for these drugs and can be manipulated to limit the viral entry and replication within the cells.Different strategies aimed at blocking ACE2 with small molecules,peptides,and antibodies,or by neutralizing the virus through its competitive binding with human recombinant soluble ACE2(hrsACE2)are currently under investigation.In this article,we review the current state of knowledge that em-phasizes the need to find effective therapeutic agents against COVID-19 by exploiting ACE2 as a potential target.The increased soluble ACE2 levels and the application of hrsACE2 in patients with COVID-19 can be implemented to control the disease.It has not yet been established whether hypertension and other comorbidities,independent of age,have a direct role in COVID-19.Therefore,the use of renin-angiotensin system inhibitors,ACEls and ARBs,should not be discontinued during COVID-19 treatment.